Vaisala’s Q1/24 was soft as expected yet delivered slight earnings beat vs.
Setanaxib delivers promising results when used together with Keytruda in a tumour type, where Setana...
Decelerating org. growth but strong cash flow '24e-'26e adj.
IRL757 Ph 1 received regulatory approval SAD/MAD study to finish by YE'24 Results expected in Q1'25e...
Q1 EBIT of SEK 5m, below ABGSC and consensus at SEK 26m AUM down 1% q-o-q driven by a finalized AM m...
Redeye makes some minor estimate changes following the report (lowering sales from TUBEX in Africa),...
VibroSense redovisade en nettoomsättning om 0,5 MSEK (0,5) i kvartalet, vilket var en minskning med ...
Calliditas entered 2024 with a strong Tarpeyo patient enrollment.
Redeye updates on EG7 ahead of Q1-results (due 14 May) where we expect a seasonally soft quarter wit...
Redeye states the report was below expecations across the board.
Redeye updates its estimates and valuation following Mentice’s Q1 2024 report.
CapMan's Q1 came in significantly above LSEG Data & Analytics consensus expectations, mostly explain...
Redeye notes that Nanexa’s Q1 report offered no material surprises, with revenues at SEK7.
Even excluding positive one-offs, the start of the year was satisfactory as Q1 is a low-season quart...
Vaisala’s Q1 net sales were in line with the previously given preliminary sales figures at EUR 112m,...
CapMan's turnover in Q1 amounted to EUR 18.4m, above our estimates and consensus (EUR 14.
Redeye is very encouraged by the strong order intake during the quarter, which came in c70% above ou...
EcoRub (”EcoRub” eller ”bolaget”) publicerade den 2 maj 2024 bolagets delårsrapport för det första k...
Redeye provides its initial take on Mentice’s Q1 2024 report, which came in considerably below our e...
Redeye was hoping for higher top-line growth. But Q1 is historically a slow quarter, and we don’t kn...
